LeMaitre Vascular (LMAT) Q2 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) reported Q2 2026 revenue of $70.4 million, up 10% organically, with diluted EPS of $0.74 (+23%). Gross margin rose to 72.1%. Artegraft sales grew 34% and now 21% of sales, while catheter sales fell 11%. Full-year guidance: revenue $274.3M-$278.3M, EPS $2.84-$2.94.
How this was made
The 30-second read
Why it matters
Traders can update models based on the provided Q2 results and the full-year ranges for revenue, EPS, and gross margin, while monitoring quantified headwinds (cardiac supply constraints, export delays) and regulatory/clinical timelines (FDA facility observations, Quick Stick trial likely in years).
Market read
The article is a company-specific earnings/guidance disclosure with multiple numeric ranges and quantified risks, making it actionable for near-term estimate revisions.
What to watch
FDA facility reaudited in June 2026 with only three of four observations addressed, and the Quick Stick clinical trial timeline is now measured in years, which could weigh on longer-dated expectations.
Background
This is a transcript-style summary of LeMaitre Vascular’s Q2 2026 earnings call, including product performance, regional growth, and updated full-year guidance.
Ticker impact
LeMaitre reported Q2 2026 revenue of $70.4M and raised full-year EPS guidance to $2.84-$2.94, alongside gross margin guidance of 72.4%.
Moderately positive bias for the next few sessions as traders price in higher EPS and margin, tempered by supply and geopolitical underperformance risk.
The article provides multiple concrete forward-looking datapoints (revenue, EPS, gross margin ranges) and quantifies headwinds (cardiac supply constraints, $400k export delays) that can affect estimates and revisions.
Market effects
Reinforces demand strength in vascular access products (Artegraft) while highlighting ongoing supply constraints in cardiac allografts, relevant for medtech tissue supply expectations.
EMEA and APAC both grew 18% in the quarter, suggesting continued international momentum despite Middle East-related export delays.
Geopolitical shipping disruption is explicitly quantified ($400k delayed orders), which can influence near-term revenue timing assumptions for global tissue exporters.
Counterpoint
The guidance update may still embed execution risk, since cardiac allograft growth is explicitly hampered by supply constraints and export delays already underperformed the quarter.
Key entities
- companyLeMaitre Vascular
Reported Q2 2026 results and provided full-year guidance updates, including EPS $2.84-$2.94 and gross margin 72.4%.
- executiveGeorge LeMaitre
CEO who discussed relocalization shipping cost benefits, regulatory progress, and longer-term clinical/regulatory timelines.
- executiveDorian LeBlanc
CFO who presented the financial takeaways and guidance ranges during the call.
